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Abstract
Background Having large congenital melanocytic naevi (CMN) is associated with a psychosocial burden on patients and
their parents because of its remarkable appearance and the extra care it may require. Large CMN also pose an increased
risk of malignant melanoma or neurocutaneous melanosis. There is a lack of international consensus on what important
outcome domains tomeasure in relation to treatment. This makes it difficult to compare options, to properly inform patients
and their parents, and to set up treatment policy for CMN. Therefore, we aim to develop a core outcome set (COS), i.e. the
minimum set of outcomes that are recommended to bemeasured and reported in all clinical trials of a specific health condi-
tion. This COS can be used in the follow-up of CMN patients with or without treatment, in clinical research and practice.
Methods In the Outcomes for Congenital Melanocytic Nevi (OCOMEN) projects, we follow the recommendations from
the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the Cochrane Skin Core Outcomes Set Initia-
tive (CS-COUSIN). This project entails the following: (i) a systematic review to identify the previous reported outcomes in
literature; (ii) focus groups with national and international patients and parents to identify patient-important outcomes; (iii)
classification of outcomes into outcome domains; (iv) e-Delphi surveys in which stakeholders (patients/parents and pro-
fessionals) can rate the importance of domains and outcomes; and (v) an online consensus meeting to finalize the core
outcome domains of the COS.
Results The results will be disseminated by means of publication in a leading journal and presentations in international
meetings or conferences. We engage international experts in CMN, both patients and professionals, to ensure the inter-
national utility and applicability of the COS.
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Introduction
Scientific background and relevance
Congenital melanocytic naevi (CMN) are birthmarks that
sometimes cover large areas of the body.1–4 They are present
at birth or appear within 3 months after birth. An estimated
1% of infants worldwide are born with CMN. However, large
[>20 cm projected adult size (PAS)] and giant (>40 cm PAS)
are rare, with an estimated incident of 1 : 20.000 and
1 : 50.000 infants, respectively.5 CMN may be associated with
a psychosocial burden on patients and their families due to
†Shared first author.
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their remarkable appearances and the extra care.6 Large CMN
also pose an increased risk of malignant melanoma, soft-tissue
tumours or neurocutaneous melanosis.7 Adequate treatment
and monitoring the impact of CMN on patients’ lives are
therefore crucial. Different interventions for CMN such as
laser, curettage and excision are available,7 but conservative
management such as watchful waiting is also possible. Patients
with large CMN may undergo several surgeries, which do not
always yield satisfactory cosmetic and functional results. It is
also not clear whether these surgeries reduce the risk of mela-
noma.7 Moreover, guidance on how to perform and the fre-
quency of watchful waiting is not available. Scientific evidence
on the best treatment policy in CMN is unfortunately still
lacking.
To date, multiple articles describe the impact of having CMN
or the effects of treatment on the lives of patients. However, a
wide heterogeneity in outcomes used in these articles makes it
difficult to combine, compare or contrast the results. Develop-
ment of a ‘core outcome set’ (COS), i.e. the minimum set of
outcomes that should be measured and reported in all clinical
trials for a specific health condition, is an effective method to
reduce heterogeneity and reporting bias in future CMN
research.8 In a strict sense, a COS consists of ‘what’ (outcome
domains) and ‘how’ (outcome measurement instruments) to
measure.9 This project, the Outcomes for Congenital Melanocy-
tic Nevi (OCOMEN), focuses first on the development of the
core outcome domains, and what specific outcomes these
domains need to cover. We define a domain as an aspect of dis-
ease that should be measured such as cognitive functioning,10
whereas an outcome describes a subgranular concept/construct
of a domain such as learning difficulties or memory lapse.11 We
aim to reach consensus on the core domains of the COS and ini-
tiate the selection of the outcomes of the domains that can be
used in the follow-up of the CMN patients without, during and
after treatment. We focus on patients with medium and larger
sizes of CMN.12
Key objectives
The key objectives of the Outcomes for Congenital Melanocytic
Nevi (OCOMEN) projects are as follows:
• To identify a list of outcomes as previously reported in the
literature and proposed by patients/parents in the focus
groups;
• To try to reach consensus on the domains and outcomes
from the perspective of professionals and patients/parents;
• To compare those domains and outcomes from the per-
spectives of the professionals with those of the patients/par-
ents; and
• To integrate the domains and outcomes important to
professionals and patients/parents into a combined set
of core outcome domains for clinical research and for
practice
Scope definition and applicability of the COS
• Population: patients with medium size or larger CMN
(Fig. 1).12 This includes those patients with M1 (1.5–10 cm
PAS) on the face or M2 (>10–20 cm PAS) elsewhere, either
single or multiple. We chose this subgroup of patients with
CMN because we expect that having medium size of CMN
or larger may have a ‘considerable’ impact on patients’ lives.
• Intervention: surgical (laser/curettage/excision) and conser-
vative (watchful waiting).




The research team consists of the ‘Study Management Group’
(SMG) and the ‘Study Advisory Group’ (SAG). The SMG is respon-
sible for the day-to-day management of the study. It consists of two
CMN experts, three methodological experts, four researchers, two
plastic surgeons and three dermatologists, and one patient represen-
tative. The SAG consists of international CMN experts who provide
their input at critical points of the study such as protocol develop-
ment, stakeholder recruitment and the consensus meeting. The
SMG and SAG both participated in the consensus process.
Study design
The OCOMEN project is registered at the Core Outcome
Measures in Effectiveness Trials (COMET) website (http://www.
comet-initiative.org/studies/details/1124) and the Cochrane Skin
Figure 1 Congenital melanocytic naevi of a patient with medium
size naevi on the face (upper) and of a patient with giant naevi on
the lower back trunk (lower).
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Core Outcomes Set Initiative (CS-COUSIN) website (http://
cs-cousin.org/cos-project-groups). We used the guidelines of the
COMET initiative and the CS-COUSIN.9,13,14
The study is done in two phases:
Phase 1: Identification of potential outcomes and domains
important in clinical research and practice by means of:
1 A systematic review and review of clinical guidelines.
2 Focus group with patients and parents to include patient-
important outcomes.
3 Classification of outcomes into domains.
Phase 2: A consensus process where relevant stakeholders (pa-
tients/parents and professionals) can rate the importance of the
identified list of outcomes and domains to reach consensus on
the domains of the COS. This is done by means of
1 Three rounds of e-Delphi survey.
2 Consensus meeting.
Phase 1: Identification of potential outcomes and domains
Phase 1.1: Systematic review The systematic review was regis-
tered in PROSPERO number CRD42018095235. We included all
research that focuses on patients with CMN, regardless of age or
sizes and locations of CMN. We looked at all types of CMN treat-
ment: interventional (laser, curettage and excision) and conserva-
tive (watchful waiting). We did not perform quality assessment of
methodological quality of the studies because we aim to include all
outcomes regardless of the methodological quality of the studies.
We searched in PubMed, EMBASE (Ovid) and the Cochrane
Library for relevant studies published between 2006 and 2018.
We chose the year 2006 because Krengel et al.12 published an
article that year about the risk of melanoma being lower than
previously thought. From then on, the focus of CMN treatment
may have shifted to favour cosmetic results rather than preven-
tion of melanoma. We engaged a clinical librarian to help with
the search terms. Key words, MeSH terms and synonyms of
‘Nevi’, ‘Congenital’ or ‘Giant’ were used.
All English, Dutch, Italian or French human studies with 10
or more CMN patients that completed the investigated interven-
tion were included. Original articles and systematic reviews are
included, whereas letters to the editor, case reports, conference
reports, books and descriptive reviews are excluded. Evidence of
CMN diagnosis by means of histology or dermatoscopy is lack-
ing. Therefore, we excluded studies that diagnosed CMN solely
by histology or dermatoscopy.
Two reviewers selected articles and extracted the data inde-
pendently. Disagreement was resolved by discussion and by con-
sulting a third review author if necessary. The following data
were extracted from the articles: authors, year of publication,
study design, intervention, objectives, number of patients, age
and gender of patients, location of CMN, size CMN, size classifi-
cation system used and outcomes reported in the methods or
results, including patient-reported outcomes and outcome mea-
surement instruments. Information about outcome measure-
ment instruments can later be used in a follow-up study on
defining the core set of outcome measurement instruments for
the domains identified in the current study.
We assessed the following: what outcomes and outcome mea-
surement instrument are used, consistency in outcomes, number
of times an outcome was used, number of patient-reported out-
comes, consistency in size classification used, correlation
between reported outcomes and size of CMN (when there is
consistency in classification tools of the size of CMN) and corre-
lation between outcomes and visibility of CMN (when descrip-
tions of visible CMN are available).
To exhaust all potentially relevant outcomes for CMN, we
also looked at existing guidelines. We found one guideline devel-
oped for clinical care of CMN patients.7
Phase 1.2: Focus groups The SMG worked together in recruit-
ing patients and parents for the national focus groups. We also
involved patients and parents from Europe and the United States
through collaboration with the SAG and the international
Table 1 Summary of the focus group discussions
No Date Location Parents/family Patients
1 5 July 2018 Erasmus MC,
the Netherlands
4 Dutch parents of giant CMN
patients. All patients were treated
–
2 6 July 2018 Erasmus MC 5 Dutch parents 3 Dutch patients (2 teenagers and 1 child).
All patients were treated
3 31 July 2018 Erasmus MC 3 Dutch parents.
All patients were treated
–
4 12 September 2018 Paris, France 7 multinational parents 3 patients from European countries,
all were treated
5 19 September 2018 Amsterdam UMC,
the Netherlands
2 Dutch parents 4 Dutch patients (1 not treated)
6 20 September 2018 Online – 4 patients in the United States and
Canada (3 not treated)
7 24 September 2018 Amsterdam UMC 1 Dutch family member 4 Dutch patients. All were treated
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patient support groups. A topic list, which contains open ques-
tions in lay language, was prepared. Questions ranged from the
impact of having CMN on patients’ lives to experiences with
treatment. Experienced researchers in the focus group discus-
sions facilitated the sessions. Participants signed an informed
consent prior to each session. Participation is treated confiden-
tially and semi-anonymously. Participants in a focus group knew
who were participating in the same group, but they did not
know other participants in the other focus groups.
We conducted three focus groups at the Erasmus MC, two at
the Amsterdam UMC, the Netherlands, one in Paris, France, and
one online by means of GoToMeeting application. The focus
groups in the Netherlands were conducted in Dutch. Table 1
summarizes the stakeholders’ background of the focus groups.
The process was audio-recorded, transcribed and analysed for
content. Full data analysis was not done in this study as the pur-
pose of these qualitative data was to identify the outcome. In the
analysis, themes were picked up and grouped (Box 1). The
themes from the Dutch focus groups were translated into
English by two of our researchers.
Phase 1.3: Classification of outcomes into domains Outcomes
identified in the review and focus groups were classified into
domains by following the taxonomies published by the COMET
initiative website.10,15 Since CMN is a specific skin condition, we
also consulted the WHO website for a more detailed classifica-
tion of the skin anatomy and functions (http://apps.who.int/clas
sifications/icfbrowser/).
Two researchers did this grouping independently. Differences
were discussed and solved by the SMG. The preliminary list of
outcome domains is included in the consensus process (Fig. 2).
Phase 2: Consensus process
Phase 2.1: Delphi study Relevant stakeholders were presented
with the identified list of domains and outcomes. They were
asked to rate the importance of these domains and outcomes in
three rounds of e-Delphi surveys. Stakeholders consist of two
groups: patient/parents and professionals. We approached the
stakeholders by the aid of international patient support organi-
zations, among other patient networks from the UK, Germany,
Belgium and the Netherlands. A detailed description of stake-
holders’ recruitment and methods used to approach them is pre-
sented in Table 2. Patients/parents who showed interest in
participating were formally invited through email. There is no
guideline to optimal sample size for the Delphi method.16,17 In
general, having more participants will increase the reliability of
groups’ judgement.18 Nevertheless, a small sample size of experts
in the field of interest can provide reliable knowledge.17 We
aimed at having 100 participants in total (patients/parents and
professionals). Variable response rates in Delphi studies have
been reported.17,19 We anticipated a response rate around 30%
to the invitation for participation. Therefore, we invited around
300 stakeholders in equal proportion to participate in the study.
We prepared the list of domains and outcomes in lay lan-
guage. A patient/parent representative and a native English
speaker reviewed the test version of the survey to ensure clarity
and ease of use. We informed participants that agreeing to
Box 1 Themes abstracted from the transcripts of the focus
groups
1. Lack of information on the condition
2. Frightening when first time see the CMN
3. Try to cover the naevi vs. not bothered by visibility of
naevi
4. Very self-conscious about the naevi
5. Try to find others with the same condition
6. Satisfied with treatment choice
7. Scare of bullying
8. Understanding/knowing about the condition helps with
coping
9. Acceptance of having the CMN
10. Support from a therapist or psychologist is well-
appreciated
11. Negative body image
12. Dark) colour of the naevi
13. Hairiness of the naevi
14. Satisfied with life
15. Scars
16. Comfortable with having scars
17. Skin graft
18. Support from patient network
19. The risk of having cancer
20. Work on the body image
21. Would not recommend to have surgeries
22. Having CMN has made a patient tough (affects the
personality)
23. Rejection (hard making friends) because of CMN
24. Missed (3 years of) school due to surgeries
25. Support from school
26. Parents’ behaviour influences the way a patient sees the
CMN
27. Itch
28. Asymmetrical size of body parts due to the naevi
29. Accept CMN as a natural tattoo (in a cool way)
30. Very emotional period around the first-time diagnosis
and surgeries
31. Addiction to morphine
32. Neurological complications
33. Feeling guilty because of having a CMN child
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participation implies that participants give consent to retaining
their background information and their rating anonymously.
Participants were given 1–2 weeks to fill out the survey, and
reminders were sent frequently. If the response rate is <70%, an
extra week is given to accomplish the task. Only participants
who completed a round will be invited for the subsequent
round.
Table 3 presents the geographical distribution of the stake-
holders who completed the first round of the Delphi study.
Definition of consensus. For the domains, we used the 9-point
Likert scoring system, where 1–3 signifies a domain of limited
importance, 4–6 somehow important but not critical and 7–9
critical. Domains will be defined as ‘important’ when scored 7–9
Domains for Congenital Melanocytic Nevi grouped










































Figure 2 Preliminary list of outcome domains presented in five core areas for the e-Delphi rounds.
Table 2 Stakeholders groups and methods of approaching potential participants
Stakeholder groups Details Methods of approach
Patients and parents Patients
Parents/caregivers*
Family members
• Identification via the Erasmus MC and Amsterdam UMC database. Invitation to
participate is done via email
• Call for participation, in collaboration with patient advocates, on the websites and
social media of international patient support organizations such as Naevus Network
Netherlands, Naevus Global, N€avus-Netzwerk Deutschland, Nevus Outreach, Caring








• Identification of names from the literature, attendance of meetings/conferences in
paediatric dermatology/plastic surgery and trough personal network of the SMG.
Invitation to participate is done by email
• Snowball-sampling method: Ask professionals to suggest names of other professionals
who may be interested to participate. We approached those names by email and invited
them to participate
• Call for participants on the Naevus International website and their first meeting in
Paris, France (12 September 2018)
* Parents can fill out the survey based on their own personal perspective or on behalf of their young child. In the latter case, they need to do the rating based
on the child’s perspective.
**Patients/parents who also happen to be one of the professionals can choose in which role (as a professional or patient/parent) they would like to fill out the
survey.
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by at least 70% of participants in each stakeholder groups in the
previous round, ‘unimportant’ when scored 1–3 by 70% of par-
ticipants and ‘undecided’ when not in any of those two groups.
For the outcomes, we define consensus to have been reached
if the outcomes are suggested to be included in a particular
domain by at least 70% of participants from each stakeholder
group. Outcomes are only scored during the third Delphi round.
First round. In the first round, a list of domains was presented
to the participants together with information on the aim and
structure of the survey. For each domain, a list of outcomes was
presented for illustration purposes. Participants needed to indi-
cate how important they find a domain is for the clinical
research setting and how important they find it is for the prac-
tice. They could also provide comments to elaborate why they
deemed a certain domain important. Participants could suggest
additional domains, which will be included in the next round if
only they are suggested by at least two participants from either
stakeholder groups.
Second round. In the second round, we aimed to reach conver-
gence on the domains. We asked the participants to rate the
domains in a similar fashion, but based on the first round, the
domains are highlighted in the following categories: ‘important’,
‘unimportant’ and ‘undecided’. They had the opportunity to
change their ratings. Additional domains suggested in the previ-
ous round were also rated.
Third round. In the third round, participants are asked to only rate
the domains that are in the ‘undecided’ category. Domains in the
‘important’ category will be highlighted but cannot be re-rated.
Domains that were scored as ‘unimportant’ in the second round
will not be retained in the third round. ‘Important’ and ‘unimpor-
tant’ domains can only be re-scored in this round if at least two
participants from either stakeholder groups propose to do so.
Stakeholders will also be asked to rate the importance of the out-
comes for each domain in the ‘important’ or ‘undecided’ category.
Feedback. Between rounds, the rating of domains in the previous
round is aggregated across stakeholder groups and summary statis-
tics are presented. We looked at the rating for the clinical research
and for practice separately. Domains are summarized in the ‘im-
portant’, ‘unimportant’ and ‘undecided’ categories. Domains that
are considered to be ‘important’ after the second round will be
directly included in the COS, while domains in the ‘unimportant’
category will be excluded and not be retained in the third round.
The abovementioned rules to reach consensus are often used,
but there are also other rules being used in other COS develop-
ment studies.20
Phase 2.2: Determination of the core set of domains of the
COS during the consensus meeting To reach consensus and
finalize the core set of domains of the COS, we will organize an
online consensus meeting. We will involve the SAG and repre-
sentatives of stakeholders who completed the 3-round surveys.
We will include equal proportion of patients/parents and profes-
sionals in this consensus meeting. The stakeholder representa-
tives will be randomly selected from those Delphi completers
who noted that they are interested in participating. Participants
will be sent a reminder of their personal Delphi scoring prior to
the meeting. We have the following criteria for inclusion of
domains and outcomes into the COS:
Selection of domains. Domains for which consensus definition
has been reached during the Delphi will be included in the core
set of domains of the COS.
Domains that are still considered ‘undecided’ after the third
Delphi round will be evaluated during the consensus meeting.
During this meeting, we will discuss and vote whether or not a
domain should be included in the final COS. A domain that
reaches at least 70% positive vote from the meeting participants
will be included, otherwise not.
Selection of outcomes in the selected domains. Once the domains
for the core set of domains of the COS have been selected, we
Table 3 Country of residence of participants of the e-Delphi study
No Countries Number of participants (%)
1 Argentina 2 (1)
2 Armenia 1 (1)
3 Australia 1 (1)
4 Belgium 4 (3)
5 Brazil 1 (1)
6 Canada 4 (3)
7 Czech Republic 3 (2)
8 Denmark 2 (1)
9 Finland 1 (1)
10 France 8 (6)
11 Germany 5 (3)
12 Greece 1 (1)
13 India 1 (1)
14 Ireland 1 (1)
15 Israel 1 (1)
16 Italy 5 (5)
17 South Korea 2 (1)
18 Netherlands 43 (30)
19 Norway 3 (2)
20 Poland 1 (1)
21 Romania 1 (1)
22 Slovakia 1 (1)
23 South Africa 1 (1)
24 Spain 4 (3)
25 Switzerland 4 (3)
26 UK 17 (12)
27 USA 26 (18)
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will select the outcomes to be included in those domains. Out-
comes that are selected by at least 70% of participants in the
third Delphi round will be automatically included in the COS.
Outcomes for which consensus definition during the Delphi has
not been reached will be voted here. An outcome for which at
least 70% positive votes have been reached during the meeting
will be included in the COS.
Ethics and consent
We have applied for ethical approval prior to the implementa-
tion of this project from the METC board at the Erasmus Medi-
cal Center and Amsterdam University Medical Center. In this
project, we collected information from patients on their health
status and experiences with treatments. Informed consent for
each of the participating patients is sought prior to participation.
We will treat all information confidentially and partially anony-
mously. The data will be treated anonymously in the analysis,
but the email addresses of each participant are encoded in the
data as an identifier. However, participants cannot know who
the other participants are and what information they provide.
Results
We will report the results separately for the systematic review
and the focus groups with the consensus process. We will pre-
sent the selected core set of domains of the COS separately for
clinical research and practice.
Dissemination and publication
The protocol and the actual development process will be
reported transparently using the COS-STAR guidance.21 The
results will also be disseminated by means of publication in lead-
ing journals and presentation in international meetings/confer-
ences. We will engage international experts in CMN, patients
and professionals to ensure an international dissemination, util-
ity and applicability of the research outcomes.
Future research plan
The scope of this research is limited to the core outcome
domains. Future research would be to define the core set of out-
come measurement instruments of the COS.
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